AssetMark Inc
OSIR

AssetMark Inc’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

AssetMark Inc’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-22
Closed – – 1552
2016
Q4 		$0 Buy
+22
New +$113 ﹤0.01% 1471

Other funds holding OSIR

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return
Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

AssetMark Inc's OSIR Position: Q1 2017 in Review

AssetMark Inc sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 22 shares.

AssetMark Inc first reported a position in OSIR in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

  • AssetMark Inc reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • AssetMark Inc sold 22 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017.
  • AssetMark Inc first reported a position in Osiris Therapeutics, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • AssetMark Inc's Osiris Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2016.
  • 11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on AssetMark Inc's 13F filing for Q1 2017, filed 9 May 2017.